- Home
- CLLS vs OCCI Comparison
CLLS vs OCCI Comparison
Compare CLLS & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- OCCI
- Stock Information
- Founded
- CLLS 1999
- OCCI N/A
- Country
- CLLS France
- OCCI United States
- Employees
- CLLS N/A
- OCCI N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- CLLS Health Care
- OCCI Finance
- Exchange
- CLLS Nasdaq
- OCCI Nasdaq
- Market Cap
- CLLS 144.4M
- OCCI 146.8M
- IPO Year
- CLLS 2007
- OCCI N/A
- Fundamental
- Price
- CLLS $1.53
- OCCI $6.66
- Analyst Decision
- CLLS Buy
- OCCI
- Analyst Count
- CLLS 3
- OCCI 0
- Target Price
- CLLS $7.00
- OCCI N/A
- AVG Volume (30 Days)
- CLLS 84.6K
- OCCI 115.8K
- Earning Date
- CLLS 05-27-2025
- OCCI 12-11-2023
- Dividend Yield
- CLLS N/A
- OCCI 24.32%
- EPS Growth
- CLLS N/A
- OCCI N/A
- EPS
- CLLS N/A
- OCCI N/A
- Revenue
- CLLS $49,217,000.00
- OCCI N/A
- Revenue This Year
- CLLS $48.52
- OCCI N/A
- Revenue Next Year
- CLLS $5.17
- OCCI $10.19
- P/E Ratio
- CLLS N/A
- OCCI N/A
- Revenue Growth
- CLLS 435.38
- OCCI N/A
- 52 Week Low
- CLLS $1.10
- OCCI $5.47
- 52 Week High
- CLLS $3.32
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- CLLS 56.17
- OCCI 53.35
- Support Level
- CLLS $1.54
- OCCI $6.49
- Resistance Level
- CLLS $1.65
- OCCI $6.79
- Average True Range (ATR)
- CLLS 0.08
- OCCI 0.12
- MACD
- CLLS -0.00
- OCCI 0.02
- Stochastic Oscillator
- CLLS 58.62
- OCCI 77.97
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.